Strategies for the treatment of HER2+ advanced breast cancer based on clinical practice in Chinese patients: a roundtable discussion
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Human epithelial growth factor receptor 2-positive (HER2+) breast cancer requires new treatments after standard therapies fail. Margetuximab shows promise as a later-line therapy, potentially improving outcomes for patients with advanced HER2+ metastatic breast cancer.
Area Of Science
- Oncology
- Immunology
Background
- HER2+ breast cancer is aggressive and prone to relapse, with limited treatment options after second-line therapy.
- Current treatments like trastuzumab and pertuzumab are effective but do not address unmet needs in later lines of therapy.
- Small molecule tyrosine kinase inhibitors (TKIs) are used, but post-TKI treatment strategies require further definition.
Purpose Of The Study
- To explore therapeutic strategies for anti-HER2 drugs in Chinese clinical practice for HER2+ metastatic breast cancer.
- To summarize consensus and controversies in post-TKI guideline recommendations for HER2+ metastatic breast cancer.
- To provide guidance for third- or later-line treatment of HER2+ metastatic breast cancer patients pretreated with TKIs.
Main Methods
- Review of current therapeutic strategies for anti-HER2 drugs in Chinese clinical practice.
- Analysis of guideline recommendations regarding post-TKI treatment for HER2+ metastatic breast cancer.
- Discussion of margetuximab's potential role based on its mechanism of action and efficacy.
Main Results
- Margetuximab, a novel anti-HER2 antibody, demonstrates enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) compared to trastuzumab.
- There is a significant unmet need for third- or later-line treatment options for HER2+ metastatic breast cancer patients progressing after TKI therapy.
- Margetuximab presents a potential therapeutic solution for patients who have progressed on prior anti-HER2 therapies and TKIs.
Conclusions
- Margetuximab may offer a valuable therapeutic option for HER2+ metastatic breast cancer patients in third- or later-line settings.
- Further research and clinical guidelines are needed to establish optimal post-TKI treatment strategies.
- Addressing the unmet needs in later-line treatment is crucial for improving survival outcomes in HER2+ metastatic breast cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...